Exelixis, Inc. Common Stock EXEL
i
Market dataready · fetched 2026-11-12T01:42:47.895Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T00:12:09.338914623Z
FundamentalsSEC EDGAR · ready · as of 2026-10-02 · fetched 2026-11-12T01:42:47.303915+00:00
Exelixis, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 75.97 | 57.8% | 9.6% | 66.31 | 45.0% | 6.3% |
| 25Δ | 75.19 | 62.1% | 8.8% | 66.82 | 49.3% | 5.9% |
| 30Δ | 67.34 | 53.7% | 5.5% | |||
| 35Δ | 72.19 | 46.2% | 4.8% | |||
| 40Δ | 71.55 | 48.8% | 4.4% | |||
| 45Δ | 70.91 | 51.4% | 4.0% | |||
| 50Δ | 70.28 | 54.0% | 3.7% | 70.17 | 19.3% | 1.1% |
| 55Δ | 69.54 | 55.7% | 3.2% | 70.57 | 20.5% | 0.9% |
| 60Δ | 68.72 | 56.8% | 2.8% | 70.98 | 21.8% | 0.8% |
| 65Δ | 67.90 | 57.9% | 2.4% | 71.38 | 23.0% | 0.7% |
| 70Δ | 66.86 | 61.0% | 2.0% | 71.79 | 24.3% | 0.6% |
| 75Δ | 65.60 | 66.0% | 1.7% | 72.19 | 25.6% | 0.5% |
| 80Δ | 63.89 | 73.9% | 1.4% | |||
20Δ
- Pseudo strike
- 75.97
- IV
- 57.8%
- B/E move
- 9.6%
- Pseudo strike
- 66.31
- IV
- 45.0%
- B/E move
- 6.3%
25Δ
- Pseudo strike
- 75.19
- IV
- 62.1%
- B/E move
- 8.8%
- Pseudo strike
- 66.82
- IV
- 49.3%
- B/E move
- 5.9%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 67.34
- IV
- 53.7%
- B/E move
- 5.5%
35Δ
- Pseudo strike
- 72.19
- IV
- 46.2%
- B/E move
- 4.8%
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- 71.55
- IV
- 48.8%
- B/E move
- 4.4%
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- 70.91
- IV
- 51.4%
- B/E move
- 4.0%
- Pseudo strike
- IV
- B/E move
50Δ
- Pseudo strike
- 70.28
- IV
- 54.0%
- B/E move
- 3.7%
- Pseudo strike
- 70.17
- IV
- 19.3%
- B/E move
- 1.1%
55Δ
- Pseudo strike
- 69.54
- IV
- 55.7%
- B/E move
- 3.2%
- Pseudo strike
- 70.57
- IV
- 20.5%
- B/E move
- 0.9%
60Δ
- Pseudo strike
- 68.72
- IV
- 56.8%
- B/E move
- 2.8%
- Pseudo strike
- 70.98
- IV
- 21.8%
- B/E move
- 0.8%
65Δ
- Pseudo strike
- 67.90
- IV
- 57.9%
- B/E move
- 2.4%
- Pseudo strike
- 71.38
- IV
- 23.0%
- B/E move
- 0.7%
70Δ
- Pseudo strike
- 66.86
- IV
- 61.0%
- B/E move
- 2.0%
- Pseudo strike
- 71.79
- IV
- 24.3%
- B/E move
- 0.6%
75Δ
- Pseudo strike
- 65.60
- IV
- 66.0%
- B/E move
- 1.7%
- Pseudo strike
- 72.19
- IV
- 25.6%
- B/E move
- 0.5%
80Δ
- Pseudo strike
- 63.89
- IV
- 73.9%
- B/E move
- 1.4%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 38.32% | |
| 38.11% | |
| 39.69% | |
| 36.90% | |
| 37.30% | |
| 38.68% | |
| 36.12% | |
| 38.53% | |
| 37.63% | |
| 36.79% | |
| 37.46% | |
| 41.13% | |
| 43.52% | |
| 38.02% | |
| 38.15% | |
| 38.01% | |
| 39.80% | |
| 39.68% | |
| 36.56% | |
| 37.79% | |
| 37.97% | |
| 40.29% | |
| 39.60% | |
| 37.53% | |
| 41.85% | |
| 40.48% | |
| 41.88% | |
| 49.23% | |
| 40.44% | |
| 40.93% | |
| 40.08% | |
| 40.41% | |
| 42.85% | |
| 41.84% | |
| 43.34% | |
| 43.93% | |
| 45.99% | |
| 43.58% | |
| 37.26% |
Biotechnology
EYPT
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and markets ophthalmic products for the treatment of eye diseases in the United States, China, and the United…
More →FATE
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders globally. The company is…
More →FDMT
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops candidate products using its adeno-associated virus vectors. The company is headquartered in…
More →FENC
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops candidate products for use in the treatment of cancer in the United States. The company is headquartered in…
More →FLNA
FuelNation Inc., a development stage company, engages in the purchase, transportation, storage, and resale of petroleum products. The company is headquartered in West Palm Beach,…
More →FTRE
Description unavailable
More →